Xultophy Novo Nordisk at a Glance
Xultophy Novo Nordisk is a combination pharmaceutical preparation containing insulin degludec (100 units/ml) and liraglutide (3.6 mg/ml) in a fixed-ratio formulation. This dual-component insulin system represents advanced diabetes therapy technology, combining ultra-long-acting basal insulin with GLP-1 receptor agonist properties. Researchers at Stroid UK Shop investigate this preparation for its unique pharmacokinetic profile and dual mechanism of action in glucose homeostasis studies. The formulation demonstrates how modern insulin technology addresses multiple pathways simultaneously in metabolic research applications.
Laboratory Applications
Research scientists examine Xultophy for its dual-pathway approach to glucose regulation mechanisms. The insulin degludec component provides ultra-long duration of action through multi-hexamer formation and albumin binding, while liraglutide activates GLP-1 receptors to modulate glucose-dependent insulin secretion. Laboratories studying general health insulin formulations analyse this preparation’s pharmacodynamic properties compared to single-component therapies. Research applications include comparative bioavailability studies, stability testing, and formulation analysis. Scientists also investigate the synergistic effects of combining basal insulin with incretin mimetics. Advanced metabolic research facilities examine this preparation alongside SARMs and peptides for comprehensive endocrine pathway studies.
Product Specifications
| Parameter | Specification |
|---|---|
| Active Components | Insulin degludec 100 units/ml + Liraglutide 3.6 mg/ml |
| Formulation Type | Pre-filled pen injection solution |
| Storage Requirements | 2-8°C refrigeration, protect from light |
| Manufacturer | Novo Nordisk A/S |
| Research Grade | Pharmaceutical standard |
| Documentation | Certificate of Analysis available |
Research Compliance
This preparation is supplied strictly for in-vitro laboratory research purposes only. Not approved for human consumption, therapeutic use, or clinical application. Researchers must follow appropriate laboratory safety protocols when handling pharmaceutical-grade insulin preparations. Storage and handling must comply with controlled substance regulations where applicable. Intended exclusively for qualified research institutions conducting diabetes, metabolism, and endocrinology studies under proper laboratory conditions.
